Andrew Scott
Impact in
- Radiology, Nuclear Medicine and Imaging top 0.05%
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Oncology top 0.2%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
Papers in
-
- Radiopharmaceutical Chemistry and Applications 107
- Monoclonal and Polyclonal Antibodies Research 89
- Medical Imaging Techniques and Applications 84
- Radiomics and Machine Learning in Medical Imaging 35
- Oncology 161
- HER2/EGFR in Cancer Research 64
- CAR-T cell therapy research 35
- Co-authors
- Lloyd J. Old (42 shared papers)Jedd D. Wolchok (1 shared paper)Hui Kong Gan (58 shared papers)Sze Ting Lee (61 shared papers)Terrance G. Johns (31 shared papers)Sagun Parakh (21 shared papers)Antony Wilks Burgess (23 shared papers)Richard J. Simpson (5 shared papers)
- Journals
- European Journal of Nuclear Medicine and Molecular Imaging (32 papers)Journal of Nuclear Medicine (32 papers)Nuclear Medicine and Biology (16 papers)The Lancet Oncology (16 papers)Clinical Cancer Research (13 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Andrew Scott
666 papers receiving 27.9k citations
Andrew Scott's Hit Papers
Peers
Comparison fields: 5 of 212
- Radiology, Nuclear Medicine and Imaging 8.2k
- Oncology 7.5k
- Cancer Research 2.8k
- Pulmonary and Respiratory Medicine 4.8k
- Immunology 3.3k
Countries citing papers authored by Andrew Scott
This map shows the geographic impact of Andrew Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Scott more than expected).
Fields of papers citing papers by Andrew Scott
This network shows the impact of papers produced by Andrew Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Scott. The network helps show where Andrew Scott may publish in the future.
Co-authors
The 25 scholars most cited alongside Andrew Scott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 700 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Antibody therapy of cancer Hit paper breakdown → | 2012 | 1817 |
| 2 | Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes Hit paper breakdown → | 2012 | 1037 |
| 3 | [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial Hit paper breakdown → | 2021 | 847 |
| 4 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 5 | A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. | 2003 | 395 |
| 6 | 2013 | 387 | |
| 7 | 2004 | 377 | |
| 8 | 2017 | 340 | |
| 9 | 2020 | 324 | |
| 10 | 2017 | 297 | |
| 11 | Radiotheranostics in oncology: current challenges and emerging opportunities Hit paper breakdown → | 2022 | 288 |
| 12 | 1992 | 260 | |
| 13 | Medical imaging and nuclear medicine: a Lancet Oncology Commission Hit paper breakdown → | 2021 | 250 |
| 14 | 2007 | 246 | |
| 15 | 1994 | 224 | |
| 16 | PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial Hit paper breakdown → | 2022 | 205 |
| 17 | 1996 | 192 | |
| 18 | 2007 | 189 | |
| 19 | Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. | 2001 | 187 |
| 20 | 1997 | 187 |
About Andrew Scott
Andrew Scott is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Pulmonary and Respiratory Medicine, Genetics and Cancer Research, having authored 700 papers that have together received 28.9k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (107 papers), Monoclonal and Polyclonal Antibodies Research (89 papers), Medical Imaging Techniques and Applications (84 papers), HER2/EGFR in Cancer Research (64 papers), CAR-T cell therapy research (35 papers), Radiomics and Machine Learning in Medical Imaging (35 papers), Glioma Diagnosis and Treatment (32 papers) and Glycosylation and Glycoproteins Research (30 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (8.2k citations), Oncology (7.5k citations), Cancer Research (2.8k citations), Pulmonary and Respiratory Medicine (4.8k citations) and Immunology (3.3k citations). Andrew Scott has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Lloyd J. Old, Jedd D. Wolchok, Hui Kong Gan, Sze Ting Lee, Terrance G. Johns, Sagun Parakh, Antony Wilks Burgess, Richard J. Simpson, Hong Long Ji and Edouard Collins Nice. Their work appears in journals such as European Journal of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine, Nuclear Medicine and Biology, The Lancet Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.